Presentation
250mg/5mL ampoule
SAS
Role
Management of patients with severe heavy metal poisoning (e.g. arsenic, mercury or lead) where parenteral therapy is required.
All cases should be discussed with a clinical toxicologist through local toxicology service or Poisons Information Centre 13 11 26.
Dose
Give 5mg/kg IV q8h on advice from a clinical toxicologist.
Stocking recommendations
Tertiary centre | Regional centre | Rural centre | Remote centre |
---|---|---|---|
0 – 10 ampoules | 0 ampoules | 0 ampoules | 0 ampoules |
Rationale
Parenteral heavy metal chelation is rarely required. Of the available parenteral chelators, DMPS has the best safety profile. The current stocking recommendations reflect a pragmatic approach to antidote availability. DMPS is not registered for use in Australia but is available via the Special Access Scheme.
Disclaimer
Last updated: July 2023